Infectious Disease Vaccine Development

The contract involves licensing the NanoFET platform to enable rapid-response vaccine development against viral and bacterial pathogens, leveraging its unique adjuvant-free immune activation and modular antigen integration capabilities. This technology allows for swift adaptation to emerging infectious threats by streamlining the design and production of vaccines without relying on traditional immune-stimulating additives, significantly reducing development timelines and enhancing safety profiles. The work is structured as a subcontract under the Department of Energy, with performance centered at Los Alamos, New Mexico, and is targeted toward advancing national defense and public health preparedness through next-generation vaccine platforms. The opportunity is open for proposals until December 18, 2026, and falls under NAICS code 541711, indicating it targets research and development in the physical, engineering, and life sciences. The contracting entity is Triad, the DOE Contractor, and the initiative aligns with broader federal efforts to build resilient, scalable biodefense capabilities. Participants must demonstrate technical proficiency in the NanoFET platform, experience in infectious disease vaccine design, and the capacity to execute rapid development cycles under strict timelines. Success in this effort will contribute directly to scalable, next-generation immunization technologies capable of addressing current and future biological threats.